MedTrace Logo

FSH-R : Diagnostic Application for Localized Tumors in Cancerology

NCT02860481 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2023-08-24

No results posted yet for this study

Summary

FRACTal study is the first exploration of detection of FSHR as a blood biomarker for the diagnosis of cancer.

A first cohort will explore several common (e.g. breast, prostate) or rare (e.g. uveal melanoma) cancers, that are frequently treated at Institut Curie. This first cohort will include n=10 patients per histological type except for breast cancer (n=50). 100 patients are expected in this cohort.

A second cohort will explore the more promising histological type (if any) in term of incidence of detection. 100 patients are expected for this second cohort.

Conditions

Interventions

PROCEDURE

blood sample for FSHR analysis

PROCEDURE

blood sample for FSHR analysis

Sponsors & Collaborators

  • Institut Curie

    lead OTHER

Principal Investigators

  • François Clément Bidard, MD · Institut Curie

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2017-04-13
Completion
2017-04-13

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02860481 on ClinicalTrials.gov